Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963382 | 1.00 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL14410780 | 0.91 | MAPK1 (0.32) | LMNACYP2C9 | |
| SCHEMBL8263799 | 0.91 | MAPK1 (0.37) | LMNACYP2C9 | |
| SCHEMBL760237 | 0.91 | MAPK1 (0.37) | LMNACYP2C9 | |
| SCHEMBL18417269 | 0.91 | MAPK1 (0.37) | LMNACYP2C9 | |
| SCHEMBL761431 | 0.87 | MAPK1 (0.39) | — | |
| SCHEMBL761441 | 0.87 | — | — | |
| SCHEMBL14411702 | 0.84 | MAPK1 (0.37) | — | |
| SCHEMBL23430621 | 0.80 | — | — | |
| SCHEMBL4546580 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080234273-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | LMNA 2098/4885CYP2C9 929/4885 |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | GCK, GCKR, GRK4 | LMNA 3100/4885CYP2C9 774/4885 |
| US-11760755-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | LMNA 2852/4885CYP2C9 685/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | LMNA 1681/4885CYP2C9 2594/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | LMNA 815/4885CYP2C9 2201/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | LMNA 2004/4885CYP2C9 2318/4885 |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | LMNA 2891/4885CYP2C9 1484/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | LMNA 1214/4885CYP2C9 4883/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | LMNA 2114/4885CYP2C9 4864/4885 |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | GCK, GCKR, GRK4 | LMNA 2988/4885CYP2C9 891/4885 |
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | GRK4, PTGER4, GPR119 | LMNA 2030/4885CYP2C9 567/4885 |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | PAH, MAOB, TYR | LMNA 1528/4885CYP2C9 10/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | LMNA 1681/4885CYP2C9 2594/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | LMNA 4186/4885CYP2C9 623/4885 |
| US-20080234273-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, HK1 | LMNA 3205/4885CYP2C9 707/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | LMNA 2462/4885CYP2C9 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.